This retrospective, single-center study found that age had no significant effect on survival of 271 patients age 50-75 years undergoing non-myeloablative haploidentical hematopoietic cell transplantation (HCT). Median age of patients was 61 years, and 84% had intermediate- or high-/very high–risk disease. All patients received non-myeloablative T cell-replete haploidentical HCT with high-dose post-transplantation cyclophosphamide. At a median follow-up of 4 years, patients in their 50s, 60s, and 70s had 3-year progression-free survival of 39%, 35%, and 33% (p=0.65); corresponding 3-year overall survival probabilities were 48%, 45%, and 44% (p=0.66). Older patient age was associated with a significantly higher risk of grade II to IV acute GVHD, but not grade III to IV acute GVHD or chronic GVHD, which the authors attributed to older donor age.
Non-Myeloablative Haploidentical HCT in Older Patients